TCG Crossover Management, LLC
- SEC CIK
- 0001839948
- Latest filing
- Aug 14, 2026
Holdings in Q3 2023
Holdings as of Sep 30, 2023, filed Nov 14, 2023. Long positions only; changes compare share counts with Q2 2023.
- Positions
- 26
- +4 vs. Q2 2023
- Portfolio value
- $679.1M
- +$69.3M (+11.4%) vs. Q2 2023
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| GPCRStructure Therapeutics Inc. | SPONSORED ADS | 1,502,747 | $75.8M | 11.2% | +1,152,747+329.4% | Added | History |
| COGTCogent Biosciences, Inc. | COM | 5,631,042 | $54.9M | 8.1% | 00.0% | Unchanged | History |
| GERNGeron Corp | COM | 23,375,839 | $49.6M | 7.3% | −213,940−0.9% | Reduced | History |
| ANTXAN2 Therapeutics, Inc. | COM | 2,678,209 | $43.1M | 6.3% | +1,388,889+107.7% | Added | History |
| SVRASavara Inc | COM | 10,000,000 | $37.8M | 5.6% | +10,000,000 | New | History |
| TSHATaysha Gene Therapies, Inc. | COM SHS | 11,111,111 | $35.1M | 5.2% | +11,111,111 | New | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 3,395,495 | $32.7M | 4.8% | 00.0% | Unchanged | History |
| INBXInhibrx Biosciences, Inc. | COM | 1,750,387 | $32.1M | 4.7% | +1,750,387 | New | History |
| JBIOJade Biosciences, Inc. | COM | 2,201,274 | $29.9M | 4.4% | 00.0% | Unchanged | History |
| ICVXIcosavax, Inc. | COM | 3,703,704 | $28.7M | 4.2% | 00.0% | Unchanged | History |
| CMPSCOMPASS Pathways plc | SPONSORED ADS | 3,858,000 | $28.5M | 4.2% | +3,858,000 | New | History |
| VTYXVentyx Biosciences, Inc. | COM | 815,724 | $28.3M | 4.2% | 00.0% | Unchanged | History |
| TYRATyra Biosciences, Inc. | COM | 1,989,103 | $27.4M | 4.0% | 00.0% | Unchanged | History |
| MDGLMadrigal Pharmaceuticals, Inc. | COM | 179,917 | $26.3M | 3.9% | +30,000+20.0% | Added | History |
| SLNSilence Therapeutics plc | ADS | 2,104,875 | $20.7M | 3.0% | 00.0% | Unchanged | History |
| TARSTarsus Pharmaceuticals, Inc. | COM | 1,142,857 | $20.3M | 3.0% | +1,142,857 | New | History |
| RYZBRayzeBio, Inc. | COM | 869,908 | $19.3M | 2.8% | +869,908 | New | History |
| DYNDyne Therapeutics, Inc. | COM | 1,650,150 | $14.8M | 2.2% | 00.0% | Unchanged | History |
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 2,040,816 | $13.2M | 1.9% | +2,040,816 | New | History |
| KURAKura Oncology, Inc. | COM | 1,423,642 | $13.0M | 1.9% | 00.0% | Unchanged | History |
| IMVTImmunovant, Inc. | COM | 334,853 | $12.9M | 1.9% | −320,000−48.9% | Reduced | History |
| TRDAEntrada Therapeutics, Inc. | COM | 584,955 | $9.24M | 1.4% | 00.0% | Unchanged | History |
| Gracell Biotechnologies Inc38406L103 | SPONSORED ADS | 3,038,889 | $8.75M | 1.3% | +3,038,889 | New | – |
| CABACabaletta Bio, Inc. | COM | 486,795 | $7.41M | 1.1% | 00.0% | Unchanged | History |
| MRUSMerus N.V. | COM | 300,000 | $7.07M | 1.0% | 00.0% | Unchanged | History |
| CCCCC4 Therapeutics, Inc. | COM STK | 1,276,574 | $2.37M | 0.3% | 00.0% | Unchanged | History |
Sold out since Q2 2023 (4)
Positions held at the end of Q2 2023 that are gone from this filing.
| Security | Class | Shares in Q2 2023 | Value in Q2 2023 | % of portfolio in Q2 2023 | History |
|---|---|---|---|---|---|
| ISEEIVERIC bio, Inc. | COM | 2,448,829 | $96.3M | 15.8% | History |
| Vectivbio Hldg AGH9060V101 | ORD SHS | 3,113,600 | $52.9M | 8.7% | – |
| ACRSAclaris Therapeutics, Inc. | COM | 529,839 | $5.49M | 0.9% | History |
| ALPNAlpine Immune Sciences, Inc. | COM | 253,069 | $2.60M | 0.4% | History |